Roche
  • Basel, Switzerland

TECENTRIQ combination* is now approved for 1L metastatic non-squamous non-small cell lung cancer (mNSCLC).

9th Apr, 2019
TECENTRIQ, in combination with Avastin (bevacizumab) and carboplatin/paclitaxel (carbo/pac) is a new regimen indicated for 1L treatment of mNSCLC. TECENTRIQ combination* is the first cancer immunotherapy to demonstrate meaningful OS advantage in EGFR/ALK+ who have previously progressed on tyrosine kinase inhibitors (TKIs) as well as in patients with liver metastases (mets). The efficacy and safety of TECENTRIQ combination* was established in the IMpower150 clinical trial.

IMpower150


A phase III multicentre, international, randomised, open-label, 3-arm trial in mNSCLC (N=1,202) comparing TECENTRIQ+Avastin+carbo/pac vs Avastin+carbo/pac alone.



Image


TECENTRIQ combination*: delivered a statistically significant OS benefit vs Avastin + carbo/pac alone


Image

Image
HR= Hazard ratio

CI = Confidence interval

PFS at 12 months was nearly doubled in TECENTRIQ combination* vs Avastin+carbo/pac alone (38% vs 20%, HR= 0.59; 95% CI, 0.50, 0.69; P<0.0001).

TECENTRIQ combination* is the first cancer immunotherapy combination to demonstrate clinically meaningful survival in EGFR/ALK+ who have progressed on TKIs as well as in patients with liver mets.


Median OS (95% CI, 0.29, 1.03) was NR in TECENTRIQ combination* vs 17.5 months in Avastin + carbo/pac. Median OS (95% CI, 0.33, 0.82) in liver mets was 13.3 months versus 9.4 months in Avastin + carbo/pac.

Image

HR= Hazard ratio

A majority of patients responded to TECENTRIQ combination* vs Avastin+carbo/pac alone



Image

HR= Hazard ratio

CI = Confidence interval

ORR was 56.4% (95% CI, 51.4, 61.4) with TECENTRIQ combination* vs 40.2% (95% CI, 35.3, 45.2) with Avastin+carbo/pac.

TECENTRIQ combination* delivered a manageable and familiar safety profile.


  • Low incidence of immune-related ARs was observed with TECENTRIQ+Avastin+carbo/pac
  • Low incidence of ≥ grade 3 bleeding events.
  • A safety profile supported by patient-reported outcomes


Image


Test your knowledge on TECENTRIQ and cancer immunotherapy.


Take the quiz and find out how much you know about TECENTRIQ clinical trials and cancer immunotherapy.



Image

______________________________________________________________________________________________

  1. TECENTRIQ Summary of Product Characteristics. Roche. March 2019.

* TECENTRIQ combination = TECENTRIQ + Avastin (bevacizumab) + carboplatin/paclitaxel

▼ This medicinal product is subject to additional monitoring in EMA-approved countries. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events or reactions.

Full prescribing information available. Download the EU TECENTRIQ SmPC here.


@ 2019 F. Hoffmann-La Roche Ltd.
This post contains information on a product which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
Posted 9th Apr, 2019
337 views